Carbon inhibits vascular endothelial growth factor- and fibroblast growth factor-promoted angiogenesis

FEBS Letters

Volumn 581, Issue 6, 2007, Pages 1157-1160

  Murugesan, Saravanababu ^a   Mousa, Shaker A ^b   O'Connor, Laura J ^b   Lincoln II, David W ^b   Linhardt, Robert J ^a,b  

^a RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Anti angiogenic; CAM assay; Carbon; Fullerenes; Nanotubes

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CARBON; ENDOTHELIAL CELL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; FULLERENE DERIVATIVE; GRAPHITE; MULTI WALLED NANOTUBE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER; CHORIOALLANTOIS; CONTROLLED STUDY; DISEASE COURSE; DRUG PROTEIN BINDING; EMBRYO; EYE DISEASE; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; WOUND HEALING;

ANIMALS; CARBON; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; FIBROBLAST GROWTH FACTOR 2; FULLERENES; GRAPHITE; MODELS, ANIMAL; NANOTUBES, CARBON; NEOVASCULARIZATION, PHYSIOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33847729517     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2007.02.022     Document Type: Article

References (18)

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936
2. Cross M.J., and Claesson-Welsh L. FGF and VEGF function in angiogenesis: signaling pathways, biological responses and therapeutic inhibition. TRENDS in Pharma. Sci. 22 (2001) 201-207
3. Silva C.H.T.P., Leopoldino A.M., Silva E.H.T., and Taft C.A. Cancer: from angiogenesis to chemotherapy. In: Taft C.A. (Ed). Current Trends in Biotechnology (2005), Research Signpost, Kerala, India 23-39
4. Marme D. The pivotal role of VEGF in tumor angiogenesis. In: Jager M., Ksander B.R., and Zierhut M. (Eds). Immunology of Ocular Tumors (2002), Taylor & Francis, Oxfordshire, United Kingdom 61-71
5. Malonne H., Langer I., Kiss R., and Atassi G. Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors. Clin. Exp. Metast. 17 (1999) 1-14
6. Gasparini G., Longo R., Toi M., and Ferrara N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat. Clin. Pract. Oncol. 2 (2005) 562-577
7. Rhee J., and Hoff P.M. Angiogenesis inhibitors in the treatment of cancer. Exp. Opin. Pharmacother. 6 (2005) 1701-1711
8. Portney N.G., and Ozkan M. Nano-oncology: drug delivery, imaging, and sensing. Anal. Bioanal. Chem. 384 (2006) 620-630
9. Park G.E., and Webster T.J. A review of nanotechnology for the development of better orthopedic implants. J. Biomed. Nanotechnol. 1 (2005) 18-29
10. Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ. Health Perspect. 114 (2006) 165-172
11. Singh R., Pantarotto D., Lacerda L., Pastorin G., Klumpp C., Prato M., Bianco A., and Kostarelos K. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc. Natl. Acad. Sci. USA 103 (2006) 3357-3362
12. Murugesan S., Park T.-J., Yang H., Mousa S.A., and Linhardt R.J. Blood compatible carbon nanotubes - nano-based neoproteoglycans. Langmuir 22 (2006) 3461-3463
13. Bekyarova E., Ni Y., Malarkey E.B., Montana V., McWilliams J.L., Haddon R.C., and Parpura V. Applications of carbon nanotubes in biotechnology and biomedicine. J. Biomed. Nanotechnol. 1 (2005) 3-17
14. Davis F.B., Mousa S.A., O'Connor L., Mohamed S., Lin H.-Y., Cao H.J., and Davis P.J. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ. Res. 94 (2004) 1500-1506
15. Mousa S.A., O'Connor L., Davis F.B., and Davis P.J. Pro-angiogenesis action of the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated. Endocrinology 147 4 (2006) 1602-1607
16. Mousa S.A., and Mohamed S. Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy. Oncol. Rep. 12 4 (2004) 683-688
17. Ribatti D., Nico B., Vacca A., Roncali L., Burri P.H., and Djonov V. Chorioallantoic membrane capillary bed: a useful target for studying angiogenesis and anti-angiogenesis in vivo. Anat. Rec. 264 (2001) 317-324
18. Bhattacharya R., Mukherjee P., Xiong Z., Atala A., Soker S., and Mukhopadhyay D. Gold nanoparticles inhibit VEGF165-induced proliferation of HUVEC cells. Nano Lett. 4 (2004) 2479-2481